Sher Emanuele
Eli Lilly and Co., Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Expert Opin Investig Drugs. 2004 Dec;13(12):1651-4. doi: 10.1517/13543784.13.12.1651.
An excellent meeting on ion channels in drug discovery and development was organised by the Strategic Research Institute. Recent progress in the molecular and cellular biology of ion channels, their localisation and their physio-pathological roles, was presented by a selected number of academic researchers. The status of development, by pharmaceutical companies, of drugs targeting specific ion channel subtypes (e.g., AMPA receptors, nicotinic receptors, GABA(A) receptors, K(+) channels, transient receptor potential channels) and with different modalities (agonists versus potentiators) was reviewed. More comparative data on the emerging ion channel screening technologies are now available and were shared in a number of presentations. Finally, cardiac ion channel liability, in the context of drug discovery and development, was thoroughly discussed.
战略研究所组织了一场关于离子通道在药物发现与开发方面的精彩会议。一些学术研究人员介绍了离子通道分子与细胞生物学、其定位及其生理病理作用方面的最新进展。会议回顾了制药公司针对特定离子通道亚型(如AMPA受体、烟碱受体、GABA(A)受体、K(+)通道、瞬时受体电位通道)且具有不同作用方式(激动剂与增强剂)的药物的开发状况。现在有了更多关于新兴离子通道筛选技术的比较数据,并在多个报告中进行了分享。最后,在药物发现与开发背景下,对心脏离子通道风险进行了深入讨论。